Merck Millipore Announces Incoming CEO and President
News Apr 15, 2014
Dr. Batra will assume leadership effective May 15, 2014 and be based at the company’s U.S. headquarters in Massachusetts.
“As a global leader in the Life Sciences industry, I am very humbled and excited to be a part of Merck Millipore team and look forward to serving our customers globally,” Dr. Batra said. “As a former researcher who personally utilized the strong differentiated products that Merck Millipore offers, I have watched this organization develop over the past several years, and look forward to further building upon that success to bring continued value to our customers and other stakeholders.”
Dr. Batra comes to Merck Millipore from the Consumer Health division of Merck KGaA, where he successfully grew the business in established and emerging markets. He previously worked at Novartis Vaccines & Diagnostics, where he was Head of Global Public Health and Market Access. Prior to that, he served in a range of executive management positions at Novartis, including global Head of Corporate Strategy and Country President for the Pharma Business in Australia.
Dr. Batra started his career as a research engineer at Merck & Co. In 2001, he joined McKinsey where he worked across the healthcare, consumer and nonprofit sectors as a senior engagement manager. In 2004, he was appointed global Brand Director for the Wound Care Franchise at Johnson & Johnson, before joining Novartis in 2006.
Dr. Batra is a member of the WSMI (World Self Medication Industry) and the Chair of the Food Supplements Committee of the AESGP (Association of the European Self-Medication Industry).
He holds a Ph.D. in chemical engineering from Princeton University and a bachelor’s degree in chemical engineering from the University of Delaware.
A human pluripotent stem cell line has been engineered which contains two ‘suicide genes’ that induce cell death in all but the desired insulin-producing cells. This double fail-safe approach opens the door to creating safe cell-replacement therapies for people living with type 1 diabetes.READ MORE
Birch pollen allergic rhinitis is the most common chronic disorder in the Northern part of the globe, and it attributes to significant morbidity and economic burden. According to a new study, pollen allergen immunotherapy has favorable effects on the molecular events and microbiome profile in the nasal membrane.READ MORE